Myriad Pharmaceuticals, Inc. is focused on discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.